MedCity News May 10, 2022
The Series B funding round was led by DFJ Growth. Osmind helps the medical community administer treatments, and track and study the effectiveness of those treatments for 14 million U.S. patients living with moderate and serious mental illness, according to the company.
Meeting the growing mental health need has meant not only offering new treatments but putting more resources into studying the effectiveness of existing medications and therapies. That requires collecting lots of data to fill in gaps in research, which is a primary focus of Osmind—a San Francisco-based startup led by scientists, technologists and psychiatrists. To help support the work it’s doing in this area, the company announced Tuesday that it has raised $40 million to expand its platform...